The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: 10% holder buying, Insider open-market buy — insiders or holders bought while this setup is live; see the timeline.
Radar 83 (high attention) · dilution pressure high · listing risk elevated · governance risk low · runway 0.6 mo · strongest signal: Runway < 6 months (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language, negative equity, runway < 6 months) coexists with live selling machinery (offering (424b)). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 51 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 20, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-08-20; 4 prior 424B filings in 12m filing | 28 |
| Aug 20, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-08-20; 4 prior 424B filings in 12m filing | 28 |
| Aug 19, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-08-19 filing | 26 |
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 33 |
| Aug 7, 2026 | ▼ Reverse split | “reverse split” language in PRE 14A (PRE 14A) filed 2026-08-07 filing | 26 |
| Jul 30, 2026 | ▲ 10% holder buying | 10% holder open-market purchases: Kosasa Thomas 1,449,[email protected] filing | 42 |
| Jul 30, 2026 | ▲ Insider open-market buy | 1 open-market buys by 1 insider(s) (~$1,000,000) in 30d: Kosasa Thomas 1,449,[email protected] 2026-07-30 filing | 34 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.6 months runway: liquidity $358,000 as of 2026-06-30, burn $6,928,917/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 50 |
| Jun 30, 2026 | ▼ Negative equity | Stockholders' equity $-3,518,000 as of 2026-06-30 filing | 31 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $358,000 vs current liabilities $4,726,000 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · OTLK Outlook Therapeutics, Inc. · SKYE Skye Bioscience, Inc. · screener →